チカグレロルの世界市場レポート 2025年

チカグレロルの市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.4%で25億7,000万米ドルに成長します。この予測成長の主な促進要因としては、個別化治療アプローチの統合の増加、ヘルスケア支出の急増、低侵襲治療への嗜好の高まり、予防的心臓ケアの重視、政府の心臓健康プログラムの支援などが挙げられます。予測期間中に予想される注目すべき動向としては、個別化医療の進展、チカグレロルジェネリック製品の登場、医薬品開発におけるAIの活用、抗血小板療法の革新、合剤による患者のアドヒアランス向上の推進などが挙げられます。

心血管疾患の有病率の上昇は、今後数年間におけるチカグレロル市場の成長を促進すると予想されています。心血管疾患には、冠動脈性心疾患、心不全、脳卒中、高血圧など、心臓や血管に影響を及ぼすさまざまな疾患が含まれます。このような有病率の増加は、飽和脂肪、トランス脂肪、添加糖、ナトリウムの過剰摂取を含む不健康な食習慣が主な原因であり、これらは高血圧、肥満、コレステロール値の上昇など、心臓に関連する疾患の主要な危険因子の一因となっています。チカグレロルは、血小板の凝集を阻害することにより血栓のリスクを低下させ、これらの疾患の治療に重要な役割を果たします。特にリスクの高い集団において、心臓発作や脳卒中の可能性を低下させることにより、患者の予後を改善します。例えば、2024年1月、米国の非営利団体である米国心臓協会は、心血管疾患による年齢調整死亡率が2022年には10万人当たり233.3人となり、2021年の224.4人から4.0％増加したと報告しました。その結果、心血管疾患の罹患率の増加がチカグレロル市場の拡大を支えています。

チカグレロル市場の主要企業は、製品適応の拡大、市場浸透の向上、競争力強化のため、規制当局の承認を積極的に追求しています。規制当局の承認は、製品が確立された安全性、有効性、品質基準を遵守していることを保証し、製品を販売・流通させるための政府機関からの正式な認可を意味します。例えば、2025年5月、インドの製薬会社であるAlembic Pharmaceuticals Ltd.は、米国食品医薬品局（USFDA）より、チカグレロル錠90mgのジェネリック医薬品の簡略新薬承認申請（ANDA）を取得し、60mgのバリエーションも暫定承認されました。本剤は、血小板凝集を阻害し、血栓の形成を抑制することにより、心血管イベントのリスクを低下させます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のチカグレロル：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のチカグレロル市場：成長率分析
• 世界のチカグレロル市場の実績：規模と成長、2019～2024年
• 世界のチカグレロル市場の予測：規模と成長、2024～2029年、2034年
• 世界のチカグレロル：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のチカグレロル市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 90mg錠
• 60mg錠
• 世界のチカグレロル市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗血小板薬
• 抗血栓剤
• 世界のチカグレロル市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のチカグレロル市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 急性冠症候群
• 心筋梗塞
• 脳卒中予防
• その他
• 世界のチカグレロル市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院・診療所
• 外来センター
• その他
• 世界のチカグレロル市場：90mg錠のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 標準90mgチカグレロル錠
• 徐放性90mgチカグレロル錠
• 世界のチカグレロル市場：60mg錠のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 標準60mgチカグレロル錠
• 徐放性60mgチカグレロル錠

第7章 地域別・国別分析

• 世界のチカグレロル市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のチカグレロル市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• チカグレロル市場：競合情勢
• チカグレロル市場：企業プロファイル
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Sun Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis
  • Dr. Reddy's Laboratories Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Cadila Pharmaceuticals Limited
• Alkem Laboratories
• Alembic Pharmaceuticals Limited
• CCL Pharmaceuticals
• Neuland Laboratories
• Jiangxi Synergy Pharmaceutical Co. Ltd.
• Leeford Healthcare Limited
• Scimplify
• JAMP Pharma Corporation
• Actoverco Pharmaceutical Company
• CTX Lifesciences Private Limited
• DM Pharma
• Hema Pharmaceuticals Pvt. Ltd.
• Chia-Tai Tianqing Pharmaceutical Group Co. Ltd.
• Biophar Lifesciences Pvt. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• チカグレロル市場2029年：新たな機会を提供する国
• チカグレロル市場2029年：新たな機会を提供するセグメント
• チカグレロル市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Ticagrelor is an oral antiplatelet drug primarily prescribed to lower the risk of heart attacks, strokes, and other cardiovascular complications in patients with acute coronary syndrome (ACS) or a prior myocardial infarction. It functions by preventing platelet aggregation, which helps reduce the formation of blood clots in the arteries. This enhances blood circulation and decreases the chances of additional cardiovascular incidents.

Ticagrelor is available mainly in two dosage forms: 90 mg and 60 mg tablets. The 90 mg formulation is typically used under prescription to prevent clot formation in individuals diagnosed with acute coronary syndrome or those with a previous heart attack. It falls under multiple therapeutic classes, including antiplatelet and antithrombotic agents. The drug is distributed through various channels such as hospital pharmacies, retail pharmacies, and online platforms. Its primary therapeutic applications include managing acute coronary syndrome, treating myocardial infarction, preventing strokes, and other related conditions. Ticagrelor is used across diverse healthcare settings, including hospitals, clinics, ambulatory care centers, and others.

The ticagrelor market research report is one of a series of new reports from The Business Research Company that provides ticagrelor market statistics, including ticagrelor industry global market size, regional shares, competitors with a ticagrelor market share, detailed ticagrelor market segments, market trends and opportunities, and any further data you may need to thrive in the ticagrelor industry. This ticagrelor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ticagrelor market size has grown strongly in recent years. It will grow from $1.79 billion in 2024 to $1.93 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. This historical growth can be linked to factors such as the rising burden of cardiovascular conditions, an aging global population, increased public awareness regarding heart health, advancements in pharmaceutical R&D, and the growing incidence of acute coronary syndrome.

The Ticagrelor market size is expected to see strong growth in the next few years. It will grow to $2.57 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. Key drivers of this projected growth include the increasing integration of personalized treatment approaches, surging healthcare spending, rising preference for less invasive therapies, a greater emphasis on preventive cardiac care, and supportive governmental cardiac health programs. Notable trends expected during the forecast period include advances in personalized medicine, the emergence of generic ticagrelor products, the use of AI in drug development, innovations in antiplatelet therapy, and the push for improved patient adherence through fixed-dose combination medications.

The rising prevalence of cardiovascular diseases is anticipated to drive the growth of the ticagrelor market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, such as coronary heart disease, heart failure, stroke, and hypertension. This growing prevalence is largely attributed to unhealthy dietary habits, including excessive intake of saturated fats, trans fats, added sugars, and sodium, which contribute to high blood pressure, obesity, and elevated cholesterol levels-key risk factors for heart-related conditions. Ticagrelor plays a crucial role in treating these diseases by preventing platelet aggregation, thereby reducing the risk of blood clots. It enhances patient outcomes by lowering the likelihood of heart attacks and strokes, particularly in high-risk populations. For example, in January 2024, the American Heart Association, a US-based nonprofit organization, reported that the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2022, reflecting a 4.0% rise from 224.4 per 100,000 in 2021. Consequently, the increasing burden of cardiovascular diseases is supporting the expansion of the ticagrelor market.

Key players in the ticagrelor market are actively pursuing regulatory approvals to broaden product indications, improve market penetration, and enhance their competitive standing. Regulatory approvals signify official authorization from governmental bodies to market and distribute a product, ensuring it adheres to established safety, efficacy, and quality standards. For example, in May 2025, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical firm, secured an abbreviated new drug application (ANDA) from the US Food & Drug Administration (USFDA) for its generic ticagrelor tablets in 90 mg strength, along with tentative approval for the 60 mg variant. These tablets are intended to lower the risk of cardiovascular events by inhibiting platelet aggregation and preventing the formation of blood clots.

In May 2023, SERB Pharmaceuticals, a pharmaceutical company based in Luxembourg, entered into a partnership with SFJ Pharmaceuticals Inc. to further the development of a ticagrelor reversal agent. This collaboration aims to support the development, obtain U.S. regulatory approval, and commercialize bentracimab-a reversal agent designed to rapidly neutralize the blood-thinning effects of ticagrelor in patients who require emergency surgery or are experiencing severe bleeding. SFJ Pharmaceuticals Inc. is a U.S.-based pharmaceutical company that specializes in developing ticagrelor reversal agents.

Major players in the ticagrelor market are AstraZeneca PLC, Merck KGaA, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited, Cadila Pharmaceuticals Limited, Alkem Laboratories, Alembic Pharmaceuticals Limited, CCL Pharmaceuticals, Neuland Laboratories, Jiangxi Synergy Pharmaceutical Co. Ltd., Leeford Healthcare Limited, Scimplify, JAMP Pharma Corporation, Actoverco Pharmaceutical Company, CTX Lifesciences Private Limited, DM Pharma, Hema Pharmaceuticals Pvt. Ltd., Chia-Tai Tianqing Pharmaceutical Group Co. Ltd., Biophar Lifesciences Pvt. Ltd., and PhaseBio Pharmaceuticals Inc.

North America was the largest region in the ticagrelor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ticagrelor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ticagrelor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ticagrelor market consists of sales of branded oral tablets, generic ticagrelor formulations, fixed-dose combination products, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ticagrelor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report highlights the rapidly growing ticagrelor market. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ticagrelor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ticagrelor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: 90 mg Tablet; 60 mg Tablet
• 2) By Drug Class: Antiplatelet Agents; Antithrombotic Agents
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Acute Coronary Syndrome; Myocardial Infarction; Stroke Prevention; Other Applications
• 5) By End User: Hospitals And Clinics; Ambulatory Centers; Other End Users
• Subsegments:
• 1) By 90 Mg Tablet: Standard 90 Mg Ticagrelor Tablet; Extended-Release 90 Mg Ticagrelor Tablet
• 2) By 60 Mg Tablet: Standard 60 Mg Ticagrelor Tablet; Extended-Release 60 Mg Ticagrelor Tablet
• Companies Mentioned: AstraZeneca PLC; Merck KGaA; Boehringer Ingelheim International GmbH; Sun Pharmaceutical Industries Limited; Dr. Reddy's Laboratories Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ticagrelor Market Characteristics

3. Ticagrelor Market Trends And Strategies

4. Ticagrelor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Ticagrelor Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ticagrelor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ticagrelor Market Growth Rate Analysis
• 5.4. Global Ticagrelor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ticagrelor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ticagrelor Total Addressable Market (TAM)

6. Ticagrelor Market Segmentation

• 6.1. Global Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 90 Mg Tablet
• 60 Mg Tablet
• 6.2. Global Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiplatelet Agents
• Antithrombotic Agents
• 6.3. Global Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Ticagrelor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Coronary Syndrome
• Myocardial Infarction
• Stroke Prevention
• Other Applications
• 6.5. Global Ticagrelor Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Ambulatory Centers
• Other End Users
• 6.6. Global Ticagrelor Market, Sub-Segmentation Of 90 Mg Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard 90 Mg Ticagrelor Tablet
• Extended-Release 90 Mg Ticagrelor Tablet
• 6.7. Global Ticagrelor Market, Sub-Segmentation Of 60 Mg Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard 60 Mg Ticagrelor Tablet
• Extended-Release 60 Mg Ticagrelor Tablet

7. Ticagrelor Market Regional And Country Analysis

• 7.1. Global Ticagrelor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ticagrelor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ticagrelor Market

• 8.1. Asia-Pacific Ticagrelor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ticagrelor Market

• 9.1. China Ticagrelor Market Overview
• 9.2. China Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ticagrelor Market

• 10.1. India Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ticagrelor Market

• 11.1. Japan Ticagrelor Market Overview
• 11.2. Japan Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ticagrelor Market

• 12.1. Australia Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ticagrelor Market

• 13.1. Indonesia Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ticagrelor Market

• 14.1. South Korea Ticagrelor Market Overview
• 14.2. South Korea Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ticagrelor Market

• 15.1. Western Europe Ticagrelor Market Overview
• 15.2. Western Europe Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ticagrelor Market

• 16.1. UK Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ticagrelor Market

• 17.1. Germany Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ticagrelor Market

• 18.1. France Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ticagrelor Market

• 19.1. Italy Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ticagrelor Market

• 20.1. Spain Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ticagrelor Market

• 21.1. Eastern Europe Ticagrelor Market Overview
• 21.2. Eastern Europe Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ticagrelor Market

• 22.1. Russia Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ticagrelor Market

• 23.1. North America Ticagrelor Market Overview
• 23.2. North America Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ticagrelor Market

• 24.1. USA Ticagrelor Market Overview
• 24.2. USA Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ticagrelor Market

• 25.1. Canada Ticagrelor Market Overview
• 25.2. Canada Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ticagrelor Market

• 26.1. South America Ticagrelor Market Overview
• 26.2. South America Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ticagrelor Market

• 27.1. Brazil Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ticagrelor Market

• 28.1. Middle East Ticagrelor Market Overview
• 28.2. Middle East Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ticagrelor Market

• 29.1. Africa Ticagrelor Market Overview
• 29.2. Africa Ticagrelor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ticagrelor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ticagrelor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ticagrelor Market Competitive Landscape And Company Profiles

• 30.1. Ticagrelor Market Competitive Landscape
• 30.2. Ticagrelor Market Company Profiles
  • 30.2.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sun Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Dr. Reddy's Laboratories Limited Overview, Products and Services, Strategy and Financial Analysis

31. Ticagrelor Market Other Major And Innovative Companies

• 31.1. Cadila Pharmaceuticals Limited
• 31.2. Alkem Laboratories
• 31.3. Alembic Pharmaceuticals Limited
• 31.4. CCL Pharmaceuticals
• 31.5. Neuland Laboratories
• 31.6. Jiangxi Synergy Pharmaceutical Co. Ltd.
• 31.7. Leeford Healthcare Limited
• 31.8. Scimplify
• 31.9. JAMP Pharma Corporation
• 31.10. Actoverco Pharmaceutical Company
• 31.11. CTX Lifesciences Private Limited
• 31.12. DM Pharma
• 31.13. Hema Pharmaceuticals Pvt. Ltd.
• 31.14. Chia-Tai Tianqing Pharmaceutical Group Co. Ltd.
• 31.15. Biophar Lifesciences Pvt. Ltd.

32. Global Ticagrelor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ticagrelor Market

34. Recent Developments In The Ticagrelor Market

35. Ticagrelor Market High Potential Countries, Segments and Strategies

• 35.1 Ticagrelor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ticagrelor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ticagrelor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer